Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T19:17:48.659Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:17:48.659Z.

Quote observation: 2026-10-06T19:15:26.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 166,342,957
TTM revenue · period ending 2026-06-30: 0

FMP input reference: bddae1a009f0b40e7fb659cb125a310776fd64778f9839bff19075a224db575c

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

NKTX PS Ratio Metrics

PS RATIO

N/A

PS RATIO AVG TTM

N/A

PS RATIO AVG 3Y

N/A

PS RATIO AVG 5Y

N/A

PS RATIO AVG 10Y

N/A

PS RATIO AVG 15Y

N/A

PS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NKTX Competitors' PS Ratio

NKTX

Nkarta, Inc.

Current

Market Cap

$166.34M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPRX

OptimizeRx Corp.

vs NKTX

Market Cap

$165.47M

PS Ratio

1.68

TTM Avg

1.70

3Y Avg

2.13

5Y Avg

4.88

ORGO

Organogenesis Holdings Inc.

vs NKTX

Market Cap

$169.21M

PS Ratio

0.37

TTM Avg

0.85

3Y Avg

0.95

5Y Avg

1.16

CUE

Cue Biopharma, Inc.

vs NKTX

Market Cap

$169.55M

PS Ratio

4.50

TTM Avg

4.86

3Y Avg

10.20

5Y Avg

38.22

MDWD

MediWound Ltd.

vs NKTX

Market Cap

$169.59M

PS Ratio

14.30

TTM Avg

12.04

3Y Avg

9.32

5Y Avg

6.72

QTRX

Quanterix Corporation

vs NKTX

Market Cap

$162.80M

PS Ratio

1.06

TTM Avg

1.56

3Y Avg

3.32

5Y Avg

5.03

CHRS

Coherus Oncology, Inc.

vs NKTX

Market Cap

$162.23M

PS Ratio

3.18

TTM Avg

3.40

3Y Avg

1.68

5Y Avg

2.05

DTIL

Precision BioSciences, Inc.

vs NKTX

Market Cap

$170.94M

PS Ratio

3.79

TTM Avg

34.48

3Y Avg

14.27

5Y Avg

9.83

DERM

Journey Medical Corporation

vs NKTX

Market Cap

$172.13M

PS Ratio

2.52

TTM Avg

2.93

3Y Avg

2.14

5Y Avg

1.57

PEPG

PepGen Inc.

vs NKTX

Market Cap

$160.13M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Nkarta, Inc. (NKTX)	$166.34M	N/A	N/A	N/A	N/A
OptimizeRx Corp. (OPRX)vs ›	$165.47M	1.68	1.70	2.13	4.88
Organogenesis Holdings Inc. (ORGO)vs ›	$169.21M	0.37	0.85	0.95	1.16
Cue Biopharma, Inc. (CUE)vs ›	$169.55M	4.50	4.86	10.20	38.22
MediWound Ltd. (MDWD)vs ›	$169.59M	14.30	12.04	9.32	6.72
Quanterix Corporation (QTRX)vs ›	$162.80M	1.06	1.56	3.32	5.03
Coherus Oncology, Inc. (CHRS)vs ›	$162.23M	3.18	3.40	1.68	2.05
Precision BioSciences, Inc. (DTIL)vs ›	$170.94M	3.79	34.48	14.27	9.83
Journey Medical Corporation (DERM)vs ›	$172.13M	2.52	2.93	2.14	1.57
PepGen Inc. (PEPG)vs ›	$160.13M	N/A	N/A	N/A	N/A

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

NKTX PS Ratio History

DATE	PS RATIO
2021-03-25	2880871.66
2021-03-24	2955709.94
2021-03-23	3001578.57
2021-03-22	3407153.80
2021-03-19	3276790.33
2021-03-18	3359675.74
2021-03-17	3631668.66
2021-03-16	3851355.24
2021-03-15	3926998.24
2021-03-12	3925388.81
2021-03-11	3943092.49
2021-03-10	3680756.13
2021-03-09	3586604.74
2021-03-08	3346800.34
2021-03-05	3517399.44
2021-03-04	3576948.19
2021-03-03	3777321.66
2021-03-02	3906075.70
2021-03-01	3955163.18
2021-02-26	3923779.38
2021-02-25	3926998.24
2021-02-24	4150708.38
2021-02-23	4336597.03
2021-02-22	4516047.97
2021-02-19	4507196.13
2021-02-18	4478226.47
2021-02-17	4581229.70
2021-02-16	4476617.05
2021-02-12	4301189.67
2021-02-11	4182092.18
2021-02-10	4342230.02
2021-02-09	4450866.24
2021-02-08	4249688.05
2021-02-05	3841698.68
2021-02-04	3664661.88
2021-02-03	3629254.52
2021-02-02	3519008.87
2021-02-01	3022501.10
2021-01-29	3191490.78
2021-01-28	3431295.18
2021-01-27	3523032.43
2021-01-26	3591433.02
2021-01-25	3859402.36
2021-01-22	3992984.68
2021-01-21	3877106.05
2021-01-20	4108058.61
2021-01-19	4264977.59
2021-01-15	4127371.71
2021-01-14	4204624.14
2021-01-13	4406607.04
2021-01-12	4347863.01
2021-01-11	4667333.97
2021-01-08	4417068.30
2021-01-07	4466155.78
2021-01-06	4425920.14
2021-01-05	4545017.63
2021-01-04	4796892.72
2020-12-31	4946569.29
2020-12-30	5286158.08
2020-12-29	5168670.01
2020-12-28	5423763.96
2020-12-24	5566198.11
2020-12-23	6085237.84
2020-12-22	5790712.97
2020-12-21	5325589.00
2020-12-18	5032673.56
2020-12-17	5431811.08
2020-12-16	5488140.98
2020-12-15	5472046.72
2020-12-14	5600800.76
2020-12-11	5525157.76
2020-12-10	5773009.29
2020-12-09	5634598.70
2020-12-08	5005313.33
2020-12-07	3887567.31
2020-12-04	3194709.63
2020-12-03	2876043.38
2020-12-02	2736023.36
2020-12-01	2756945.89
2020-11-30	2678084.04
2020-11-27	2727976.23
2020-11-25	2844659.58
2020-11-24	2791548.54
2020-11-23	2804423.95
2020-11-20	2781087.28
2020-11-19	2738437.50
2020-11-18	2746484.63
2020-11-17	2851097.28
2020-11-16	2699811.29
2020-11-13	2561400.69
2020-08-20	346933.83
2020-08-19	355858.99
2020-08-18	369374.24
2020-08-17	342598.75
2020-08-14	356751.51
2020-08-13	342471.25
2020-08-12	310340.66
2020-08-11	308938.14
2020-08-10	299885.47
2020-08-07	306005.58
2020-08-06	317353.29
2020-08-05	321560.87
2020-08-04	334438.60
2020-08-03	338901.18
2020-07-31	328318.49
2020-07-30	347061.33
2020-07-29	337371.16
2020-07-28	347061.33
2020-07-27	353053.94
2020-07-24	365931.68
2020-07-23	386969.56
2020-07-22	393344.68
2020-07-21	428407.82
2020-07-20	463980.97
2020-07-17	472013.61
2020-07-16	463470.96
2020-07-15	466021.00
2020-07-14	459645.89
2020-07-13	491138.96
2020-07-10	610736.14

Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-25
Q1 FY2026Period ended 2026-03-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12
Q2 FY2026Period ended 2026-06-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10
TTM revenue	$0

PS Ratio: N/A

NKTX PS Ratio Chart

NKTX PS Ratio Metrics

NKTX Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

NKTX PS Ratio History

Related Metrics